Matt Hopkins


By this expert

-varn6-US Pharma’s Financialized Business Model

-varn7-Paper -varn9-Working Paper Series | | Jul 2017 -varn13-

-varn14- Price gouging in the US pharmaceutical drug industry goes back more than three decades. 

-varn6-A Public Comment on the SEC Pay Ratio Disclosure Rule

-varn7-Article | Mar 29, 2017 -varn13-

-varn14- In this comment, we explain our objections to the SEC’s current formulation of the Pay Ratio Disclosure Rule on each of three grounds: the erroneous estimation of CEO pay; the unclear specification of the “median” worker; and the risk of normalizing a pay ratio that is far too high. Then we present the latest data on the remuneration of the 500 highest-paid CEOs in the United States, demonstrating the way in which the SEC’s measure of CEO pay that enters into the CEO-to-median-worker pay ratio tends to systematically underestimate actual executive pay.

-varn6-If CEO Pay Was Measured Properly, It Would Look Even More Outrageous

-varn7-Article | Dec 22, 2016 -varn13-

-varn14- Research funded by the Institute for New Economic Thinking has revealed that the SEC reports executive compensation using a formula that routinely undercounts it

-varn6-The Mismeasure of Mammon: Uses and Abuses of Executive Pay Data

-varn7-Paper -varn9-Working Paper Series | | Aug 2016 -varn13-

-varn14- Report to the Institute for New Economic Thinking on the statistical measurement and policy implications of the compensation of the highest- paid U.S. corporate executives